KR880006205A - 치환된 1h-이미다졸 - Google Patents
치환된 1h-이미다졸 Download PDFInfo
- Publication number
- KR880006205A KR880006205A KR870012264A KR870012264A KR880006205A KR 880006205 A KR880006205 A KR 880006205A KR 870012264 A KR870012264 A KR 870012264A KR 870012264 A KR870012264 A KR 870012264A KR 880006205 A KR880006205 A KR 880006205A
- Authority
- KR
- South Korea
- Prior art keywords
- imidazole
- represent
- pharmaceutically acceptable
- hydrogen atom
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Resins (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (16)
- 다음 일반식(I)의, 광학활성 이성질체 및 라세미 혼합물을 포함하는, 치환된 1H-이미다졸 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염:상기식에서 R1,R2,R3및 R5는 각각 수소원자 또는 1개 내지 4개의 탄소원자를 갖는 알킬기를 나타내고, R4는 수소원자, 1개 내지 4개의 탄소원자를 갖는 알킬기 또는 1개 내지 4개의 탄소원자를 갖는 알콕시기를 나타내고, Y1과 Y2는 수소원자와 OZ2기중에서 하나씩을 각기 나타내고, Z1과 Z2는 각각 수소원자 또는 1개 내지 4개의 탄소원자를 갖는 알킬기를 나타내고 Z1과 Z2는 함께 -CH2-또는 -C(CH3)2-기를 나타낸다.
- R1,R2,R4및 R5는 각각 수소원자를 나타내고, R3가 수소원자 또는 1개 내지 4개의 탄소원자를 갖는 알킬기를 나타내고, Z1과 Z2는 각각 수소원자를 나타내고 Z1과 Z2가 함께 -CH2-또는 -C(CH3)2-기를 나타냄을 특징으로 하는 제1항에 따른 화합물 또는 비독성이며 약제학적으로 수용가능한 이것의 산부가염.
- 3-[(1H-이미다졸-4-일)메틸]-2-히드록시벤젠 메탄올 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 3-[(1H-이미다졸-4-일)메틸]-6-히드록시벤젠 메탄올 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 3-[(1H-이미다졸-4-일)에틸]-2-히드록시벤젠 메탄올 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 3-[(1H-이미다졸-4-일)펜틸]-2-히드록시벤젠 메탄올 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 4-[(4H-1,3-벤조디옥신-8-일)메틸]-1H-이미다졸 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 4-[1-(4H-1,3-벤조디옥신-8-일)에틸]-1H-이미다졸 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 4-[(2,2-디메틸-4H-1,3-벤조디옥신-8-일)메틸]-1H-이미다졸 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 4-[1-(2,2-디메틸-4H-1,3-벤조디옥신-8-일)에틸]-1H-이미다졸 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염임을 특징으로 하는 제1항에 따른 화합물.
- 4-[1-(2,2-디메틸-4H-1,3-벤조디옥신-8-일)펜틸]-1H-이미다졸 또는 비독성이며 약제학적으로 수용가능한 이것의 산부 가염.
- 다음 일반식(Ⅱ)의 이미다졸화합물을 환원시킴을 포함하는, Z1과 Z2가 각각 1개 내지 4개의 탄소원자를 갖는 알킬기를 나타내고 함께는 -CH2- 또는 -C(CH3)2-기를 나타내는, 제1항에 주어진 일반식(I)을 갖는 치환된 1H-이미다졸의 제조방법:상기식에서 R2,R3및 R5는 제1항에 주어진 의미를 갖고, R6는 수소원자 또는 1개 내지 4개의 탄소원자를 갖는 알킬기 R7은 제1항에 R1으로 나타난 의미를 갖거나 또는 환원에 의해 쉽게 제거될 수 있는 기이고, R8은 제1항에서 R4로 나타낸 의미를 갖거나 또는 염소원자이고, Y1과 Y2는 수소원자와 OZ2기중에서 하나씩을 각기 나타내고, Z1Z2는 상기에 주어진 의미를 갖는다.
- 다음일반식(Ⅲ)의 4-[[2,2-디메틸-4H-1,3-벤조디옥신-6(또는8)-일]메틸]-1H-이미다졸을 수성산 매질에서 가수분해시킴을 포함하는, Z1과Z2가 수소원자를 나타내는 제1항에 주어진 일반식(I)을 갖는 치환된 1H-이미다졸의 제조방법:상기식에서 R1,R2,R3,R4및 R5는 제1항에 주어진 의미를 나타내고, Y1과 Y2는 수소원자 또는 OZ2기중의 하나씩을 각기 나타내고, Z1과Z2는 함께 -C(CH3)2-기를 나타낸다.
- 다음 일반식(Ⅳ)의 알킬 3-[(1H-이미다졸-4-일)메틸]-2-히드록시벤조에이트를 환원시킴을 포함하는, Y1=OZ2이고 Y2,Z1,Z2및 R5는 수소원자인, 제1항에 주어진 일반식(I)을 갖는 치환된 1H-이미다졸의 제조방법:상기식에서 R1,R2,R3및 R4는 제1항에 주어진 의미를 갖고 R9은 1개 내지 4개의 탄소원자를 갖는 알킬기이다.
- 치료학적으로 유효량의 제1항에 따른 치환된 1H-이미다졸 및 이것을 위한 약제학적으로 수용가능한 고체 또는 액체희석제 또는 담체를 포함하는 제약조성물.
- 치료학적으로 유효량의 제1항에 따른 치환된 1H-이미다졸을 항허혈작용을 필요로 하는 환자에게 투여하는 것을 포함하는, 항허혈작용을 달성하기 위한 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8626287 | 1986-11-04 | ||
GB868626287A GB8626287D0 (en) | 1986-11-04 | 1986-11-04 | Substituted 1h-imidazoles |
GB86-26287 | 1986-11-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880006205A true KR880006205A (ko) | 1988-07-22 |
KR910003116B1 KR910003116B1 (ko) | 1991-05-18 |
Family
ID=10606751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870012264A KR910003116B1 (ko) | 1986-11-04 | 1987-10-31 | 치환된 1h-이미다졸 |
Country Status (24)
Country | Link |
---|---|
US (1) | US4814343A (ko) |
EP (1) | EP0269599B1 (ko) |
JP (1) | JP2632877B2 (ko) |
KR (1) | KR910003116B1 (ko) |
AT (1) | ATE98640T1 (ko) |
AU (1) | AU592733B2 (ko) |
CA (1) | CA1301174C (ko) |
CY (1) | CY1845A (ko) |
DE (1) | DE3788507T2 (ko) |
DK (1) | DK166584B1 (ko) |
ES (1) | ES2060608T3 (ko) |
FI (1) | FI91858C (ko) |
GB (1) | GB8626287D0 (ko) |
HK (1) | HK78895A (ko) |
HU (1) | HU206684B (ko) |
IE (1) | IE61901B1 (ko) |
IL (1) | IL84322A (ko) |
MY (1) | MY102578A (ko) |
NO (1) | NO169960C (ko) |
NZ (1) | NZ222382A (ko) |
PL (3) | PL155119B1 (ko) |
PT (1) | PT86040B (ko) |
SU (4) | SU1662349A3 (ko) |
ZA (1) | ZA878170B (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116984A (en) * | 1988-04-07 | 1992-05-26 | Glaxo Group Limited | Imidazole derivatives |
GB8810067D0 (en) * | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
JPH04252867A (ja) * | 1991-01-25 | 1992-09-08 | Nissan Motor Co Ltd | 内燃機関の燃料供給装置 |
GB9310965D0 (en) * | 1993-05-27 | 1993-07-14 | Ucb Sa | 2-hydroxy-3-(1h-imidazol-4-yl)alkyl)benzenecarboximidamides |
EP0729459B1 (en) * | 1993-11-15 | 2003-03-12 | Schering Corporation | Phenyl-alkyl imidazoles as h3-receptor antagonists |
GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9521680D0 (en) * | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
WO2008088937A1 (en) * | 2007-01-12 | 2008-07-24 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
US8013169B2 (en) * | 2007-01-12 | 2011-09-06 | Allergan, Inc | Naphthylmethylimidizoles as therapeutic agents |
WO2008088936A1 (en) * | 2007-01-12 | 2008-07-24 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US29761A (en) * | 1860-08-28 | Improvements in telegraphic apparatus | ||
US4062967A (en) | 1974-02-07 | 1977-12-13 | Smith Kline & French Laboratories Limited | Bis-guanidino-alkane compounds |
AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
DE4224020A1 (de) * | 1992-07-22 | 1994-01-27 | Deutsche Aerospace | Verfahren zur Auslösung der Zündung eines Gefechtskopfes und Anordnung zum Durchführen des Verfahrens |
-
1986
- 1986-11-04 GB GB868626287A patent/GB8626287D0/en active Pending
-
1987
- 1987-10-14 CA CA000549258A patent/CA1301174C/en not_active Expired - Lifetime
- 1987-10-30 DE DE3788507T patent/DE3788507T2/de not_active Expired - Fee Related
- 1987-10-30 PT PT86040A patent/PT86040B/pt not_active IP Right Cessation
- 1987-10-30 ES ES87870149T patent/ES2060608T3/es not_active Expired - Lifetime
- 1987-10-30 FI FI874789A patent/FI91858C/fi not_active IP Right Cessation
- 1987-10-30 NZ NZ222382A patent/NZ222382A/en unknown
- 1987-10-30 ZA ZA878170A patent/ZA878170B/xx unknown
- 1987-10-30 IL IL84322A patent/IL84322A/xx not_active IP Right Cessation
- 1987-10-30 AT AT87870149T patent/ATE98640T1/de not_active IP Right Cessation
- 1987-10-30 EP EP87870149A patent/EP0269599B1/fr not_active Expired - Lifetime
- 1987-10-31 KR KR1019870012264A patent/KR910003116B1/ko not_active IP Right Cessation
- 1987-11-02 PL PL1987268558A patent/PL155119B1/pl unknown
- 1987-11-02 PL PL1987288655A patent/PL156483B1/pl unknown
- 1987-11-02 MY MYPI87003010A patent/MY102578A/en unknown
- 1987-11-02 PL PL1987288654A patent/PL156482B1/pl unknown
- 1987-11-02 DK DK572987A patent/DK166584B1/da active
- 1987-11-02 US US07/116,325 patent/US4814343A/en not_active Expired - Lifetime
- 1987-11-02 JP JP62278144A patent/JP2632877B2/ja not_active Expired - Lifetime
- 1987-11-02 AU AU80593/87A patent/AU592733B2/en not_active Ceased
- 1987-11-03 NO NO874572A patent/NO169960C/no not_active IP Right Cessation
- 1987-11-03 SU SU874203647A patent/SU1662349A3/ru active
- 1987-11-03 IE IE296387A patent/IE61901B1/en not_active IP Right Cessation
- 1987-11-04 HU HU874948A patent/HU206684B/hu not_active IP Right Cessation
-
1988
- 1988-06-30 SU SU884356015A patent/SU1710558A1/ru active
- 1988-12-22 SU SU884613197A patent/SU1628857A3/ru active
- 1988-12-22 SU SU884613108A patent/SU1635899A3/ru active
-
1995
- 1995-05-18 HK HK78895A patent/HK78895A/xx not_active IP Right Cessation
-
1996
- 1996-03-08 CY CY184596A patent/CY1845A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3271269D1 (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
CA2036876A1 (fr) | Derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
KR880006205A (ko) | 치환된 1h-이미다졸 | |
KR900004658A (ko) | 이치환 벤질아민, 그의 제조방법, 약제로서의 그의 용도 및 그의 합성 약제 | |
KR890016017A (ko) | 치환된 1-(1h-이미다졸-4-일)알킬-벤즈아미드 | |
JPS5750989A (en) | Imidazole compound | |
KR880006239A (ko) | 기라제 억제제, 그의 제조방법 및 용도 | |
KR930000523A (ko) | 신규한 세펨 화합물 | |
KR970704685A (ko) | 신경이완제로서 유용한 N-치환 아자비시클로헵탄 유도체(N-Substituted Azabicycloheptane Derivatives Useful as Neuroleptics) | |
JPS5687568A (en) | Imidazoline compound | |
KR910000652A (ko) | (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도 | |
KR960007534A (ko) | 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도 | |
KR960704889A (ko) | 인돌리진 유도체의 제조방법 (Process for the preparation of indolizine derivatives) | |
KR920002564A (ko) | N-알킬 티아졸리딘 유도체 | |
SE8303720L (sv) | Eburnanderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande desamma | |
KR960701832A (ko) | Ng-모노알킬-l-아르기닌 및 관련 화합물의 제조 방법(process for preparing ng-monoalkyl-l-arginine and related compounds) | |
ZA838139B (en) | Semicarbazides,process for preparing these,and pharmaceutical compositions thereof | |
ATE55120T1 (de) | 3-aryl-3-pyrrolin-derivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel fuer die bekaempfung von herz- und gefaesskrankheiten. | |
KR890006626A (ko) | 고혈압치료용 벤조피란 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20000321 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |